BR112016028043A2 - composições farmacêuticas, e transportador farmaceuticamente aceitável e anticorpo monoclonal para igg3 humana ou humanizada - Google Patents

composições farmacêuticas, e transportador farmaceuticamente aceitável e anticorpo monoclonal para igg3 humana ou humanizada

Info

Publication number
BR112016028043A2
BR112016028043A2 BR112016028043A BR112016028043A BR112016028043A2 BR 112016028043 A2 BR112016028043 A2 BR 112016028043A2 BR 112016028043 A BR112016028043 A BR 112016028043A BR 112016028043 A BR112016028043 A BR 112016028043A BR 112016028043 A2 BR112016028043 A2 BR 112016028043A2
Authority
BR
Brazil
Prior art keywords
human
pharmaceutically acceptable
pharmaceutical compositions
monoclonal antibody
acceptable carrier
Prior art date
Application number
BR112016028043A
Other languages
English (en)
Other versions
BR112016028043B1 (pt
Inventor
Simard John
Original Assignee
Xbiotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xbiotech Inc filed Critical Xbiotech Inc
Publication of BR112016028043A2 publication Critical patent/BR112016028043A2/pt
Publication of BR112016028043B1 publication Critical patent/BR112016028043B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

a presente invenção trata de anticorpos tendo regiões fab que se ligam especificamente à proteína a de staphylococcus aureus são capazes de mediar a opsonização de bactérias staphylococcus aureus apesar da sua expressão da proteína neutralizante de anticorpos a. estes anticorpos e seus fragmentos de ligação ao antígeno podem ser usados em métodos de tratamento e/ou prevenção de infeções por staphylococcus aureus.
BR112016028043-1A 2014-06-03 2015-06-03 Composição farmacêutica e anticorpo monoclonal BR112016028043B1 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462007242P 2014-06-03 2014-06-03
US62/007,242 2014-06-03
US201462041423P 2014-08-25 2014-08-25
US62/041,423 2014-08-25
US201562115665P 2015-02-13 2015-02-13
US62/115,665 2015-02-13
PCT/US2015/033902 WO2015187779A1 (en) 2014-06-03 2015-06-03 Compositions and methods for treating and preventing staphylococcus aureus infections

Publications (2)

Publication Number Publication Date
BR112016028043A2 true BR112016028043A2 (pt) 2017-10-24
BR112016028043B1 BR112016028043B1 (pt) 2023-12-12

Family

ID=54700993

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016028043-1A BR112016028043B1 (pt) 2014-06-03 2015-06-03 Composição farmacêutica e anticorpo monoclonal

Country Status (19)

Country Link
US (7) US9416172B2 (pt)
EP (2) EP3154584B1 (pt)
JP (4) JP6166000B1 (pt)
KR (4) KR20190100471A (pt)
CN (2) CN106456763B (pt)
AU (2) AU2015271749B2 (pt)
BR (1) BR112016028043B1 (pt)
CA (1) CA2950840C (pt)
CL (1) CL2016003071A1 (pt)
ES (1) ES2894867T3 (pt)
IL (1) IL248959B (pt)
MX (1) MX355107B (pt)
MY (1) MY191346A (pt)
NZ (1) NZ726911A (pt)
PH (2) PH12016502372A1 (pt)
RU (2) RU2636780C1 (pt)
SG (2) SG10201703965SA (pt)
WO (1) WO2015187779A1 (pt)
ZA (1) ZA201608604B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2703774T3 (es) 2010-06-18 2019-03-12 Xbiotech Inc Tratamiento para la artritis
EP2608808B1 (en) 2010-08-23 2017-01-18 XBiotech, Inc Treatment for neoplastic diseases
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
WO2013096948A1 (en) 2011-12-23 2013-06-27 Lydon Nicholas B Immunoglobulins and variants directed against pathogenic microbes
US9988439B2 (en) 2011-12-23 2018-06-05 Nicholas B. Lydon Immunoglobulins and variants directed against pathogenic microbes
SG11201503232TA (en) 2012-11-06 2015-05-28 Medimmune Llc Antibodies to s. aureus surface determinants
ES2894867T3 (es) * 2014-06-03 2022-02-16 Xbiotech Inc Composiciones y procedimientos de tratamiento y prevención de infecciones por estafilococo áureo
KR20180104036A (ko) 2016-01-22 2018-09-19 머크 샤프 앤드 돔 코포레이션 항-응고 인자 xi 항체
PE20190416A1 (es) 2016-06-14 2019-03-19 Merck Sharp & Dohme Anticuerpos antifactor de la coagulacion xi
AU2018220862A1 (en) 2017-02-16 2019-08-29 Janssen Biotech, Inc. Treatment of hidradenitis suppurativa
WO2018237010A2 (en) 2017-06-20 2018-12-27 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College VACCINE COMPOSITIONS AGAINST STREPTOCOCCUS AND THEIR METHODS OF USE
WO2019006159A1 (en) * 2017-06-30 2019-01-03 Xbiotech, Inc. COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING STAPHYLOCOCCUS AUREUS INFECTIONS
EP3530282A1 (en) * 2018-02-27 2019-08-28 Diaccurate Therapeutic methods
CN109705213B (zh) * 2018-12-04 2023-04-18 上海长征医院 抗金黄色葡萄球菌毒素抗体及其用途
JP2022525388A (ja) * 2019-01-22 2022-05-13 クレムソン・ユニバーシティ・リサーチ・ファウンデーション 抗エラスチン抗体及び使用方法
US20200277370A1 (en) 2019-02-28 2020-09-03 Janssen Biotech, Inc. Treatment of hidradenitis suppurativa
CA3179228A1 (en) 2020-04-16 2021-10-21 Janssen Biotech, Inc. Treatment of hidradenitis suppurativa

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US5258499A (en) 1988-05-16 1993-11-02 Vestar, Inc. Liposome targeting using receptor specific ligands
DE3825429C2 (de) 1988-07-27 1994-02-10 Biotest Pharma Gmbh Verfahren zur Herstellung eines intravenös verabreichbaren polyklonalen Immunglobulin-Präparates mit hohem IgM-Gehalt
EP1997891A1 (en) 1988-09-02 2008-12-03 Dyax Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5750373A (en) 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
US5077391A (en) 1989-12-01 1991-12-31 Raison Robert L Purification of immunoglobulin M
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5111074A (en) 1990-07-26 1992-05-05 Regents Of The University Of Minnesota Multi-input compound function complementary noise-immune logic
US5112952A (en) 1990-09-28 1992-05-12 Pierce Chemical Company Composition and method for isolation and purification of Immunoglobulin M
DK1820858T3 (da) 1991-03-01 2009-11-02 Dyax Corp Kimært protein omfatende mikroprotein med to eller flere disulfidbindinger og udförelsesformer deraf
WO1992018619A1 (en) 1991-04-10 1992-10-29 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
WO1994009818A1 (en) 1992-10-30 1994-05-11 The Regents Of The University Of California Method for stimulating production of variable region gene family restricted antibodies through b-cell superantigen vaccination
US5545721A (en) 1992-12-21 1996-08-13 Ophidian Pharmaceuticals, Inc. Conjugates for the prevention and treatment of sepsis
US5770208A (en) 1996-09-11 1998-06-23 Nabi Staphylococcus aureus B-linked hexosamine antigen
EP0835880A1 (de) 1996-10-14 1998-04-15 Rotkreuzstiftung Zentrallaboratorium Blutspendedienst Srk Verfahren zur Herstellung eines IgM Präparates für die intravenöse Applikation
DE69942021D1 (de) 1998-04-20 2010-04-01 Glycart Biotechnology Ag Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität
US6322788B1 (en) 1998-08-20 2001-11-27 Stanley Arthur Kim Anti-bacterial antibodies and methods of use
US8142780B2 (en) 1998-08-20 2012-03-27 Strox Biopharmaceuticals, Llc Anti-bacterial antibodies
US6692739B1 (en) 1998-08-31 2004-02-17 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation
DK2270149T3 (en) 1999-04-09 2016-05-09 Kyowa Hakko Kirin Co Ltd PROCEDURE TO CONTROL THE ACTIVITY OF IMMUNOLOGICAL FUNCTIONAL MOLECULE.
CN102311986B (zh) 2000-10-06 2015-08-19 协和发酵麒麟株式会社 产生抗体组合物的细胞
EP1383800A4 (en) 2001-04-02 2004-09-22 Idec Pharma Corp RECOMBINANT ANTIBODIES CO-EXPRESSED WITH GNTIII
US7169903B2 (en) 2001-12-21 2007-01-30 Biosynexus Incorporated Multifunctional monoclonal antibodies directed to peptidoglycan of gram-positive bacteria
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
EP2208783A1 (en) 2004-12-22 2010-07-21 Chugai Seiyaku Kabushiki Kaisha Method of producing an antibody using a cell in which the function of fucose transporter is inhibited
JP5620626B2 (ja) 2005-03-31 2014-11-05 中外製薬株式会社 会合制御によるポリペプチド製造方法
CA2606102C (en) 2005-04-26 2014-09-30 Medimmune, Inc. Modulation of antibody effector function by hinge domain engineering
CN101074263B (zh) * 2006-05-17 2011-07-06 上海抗体药物国家工程研究中心有限公司 一种重组抗proteinA单克隆抗体及其制备方法和用途
US7488807B2 (en) 2006-11-22 2009-02-10 3M Innovative Properties Company Antibody with protein A selectivity
US7691608B2 (en) 2006-12-06 2010-04-06 Repligen Corporation Nucleic acids encoding recombinant protein A
CA2722304A1 (en) 2007-04-23 2009-02-19 Sudhir Paul Immunoglobulins directed to bacterial, viral and endogeneous polypeptides
TWI563002B (en) 2007-09-26 2016-12-21 Chugai Pharmaceutical Co Ltd Antibody constant region mutant
EP2291196A4 (en) 2008-05-12 2012-05-30 Strox Biopharmaceuticals Llc FOR STAPHYLOCOCCUS AUREUS SPECIFIC ANTIBODY PREPARATIONS
CN101339197B (zh) * 2008-07-30 2012-07-04 广州康盛生物科技有限公司 葡萄球菌蛋白a定量检测试剂盒及定量检测方法
US20100092470A1 (en) 2008-09-22 2010-04-15 Icb International, Inc. Antibodies, analogs and uses thereof
US9013699B2 (en) 2009-11-09 2015-04-21 Cantwell G. Carson Vaccine testing system
CN102971340A (zh) 2010-03-29 2013-03-13 酵活有限公司 具有增强的或抑制的效应子功能的抗体
JP2013523818A (ja) * 2010-04-05 2013-06-17 ザ・ユニバーシティー・オブ・シカゴ 免疫反応のエンハンサーとしてのプロテインＡ（ＳｐＡ）抗体に関連する組成物および方法
US20140093496A1 (en) 2011-02-25 2014-04-03 Chugai Seiyaku Kabushiki Kaisha Fc-gamma-RIIb-SPECIFIC Fc ANTIBODY
KR102139388B1 (ko) 2011-07-12 2020-07-30 엑스바이오테크, 인크. 친화성 성숙 인간 항체의 동정
JP6317670B2 (ja) * 2011-08-15 2018-04-25 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ ブドウ球菌プロテインａに対する抗体に関連した組成物および方法
SG11201402686UA (en) 2011-12-05 2014-06-27 Igenica Inc Antibody-drug conjugates and related compounds, compositions, and methods
WO2013096948A1 (en) * 2011-12-23 2013-06-27 Lydon Nicholas B Immunoglobulins and variants directed against pathogenic microbes
EP2705852A1 (en) * 2012-09-06 2014-03-12 Université de Lausanne An immunogenic composition against Staphylococcus aureus comprising an inactivated recombinant non-pathogenic bacterium
SG11201503232TA (en) * 2012-11-06 2015-05-28 Medimmune Llc Antibodies to s. aureus surface determinants
ES2894867T3 (es) * 2014-06-03 2022-02-16 Xbiotech Inc Composiciones y procedimientos de tratamiento y prevención de infecciones por estafilococo áureo

Also Published As

Publication number Publication date
CA2950840A1 (en) 2015-12-10
US9783598B2 (en) 2017-10-10
PH12018501429A1 (en) 2019-02-27
KR20170078846A (ko) 2017-07-07
NZ726911A (en) 2023-01-27
PH12016502372B1 (en) 2017-02-20
SG11201609487QA (en) 2016-12-29
AU2018200886A1 (en) 2018-02-22
BR112016028043B1 (pt) 2023-12-12
JP2022105178A (ja) 2022-07-12
RU2764981C1 (ru) 2022-01-24
CL2016003071A1 (es) 2017-09-15
EP3154584A1 (en) 2017-04-19
US20170349648A1 (en) 2017-12-07
IL248959A0 (en) 2017-01-31
RU2636780C1 (ru) 2017-11-28
US20160279243A1 (en) 2016-09-29
KR102015451B1 (ko) 2019-08-28
US10577410B2 (en) 2020-03-03
AU2018200886B2 (en) 2019-06-06
PH12016502372A1 (en) 2017-02-20
US9486523B2 (en) 2016-11-08
JP2017522275A (ja) 2017-08-10
JP6166000B1 (ja) 2017-07-19
JP2017214388A (ja) 2017-12-07
EP3154584A4 (en) 2018-06-06
US11370831B2 (en) 2022-06-28
ZA201608604B (en) 2018-05-30
US20150344548A1 (en) 2015-12-03
EP3970747A3 (en) 2022-10-05
MY191346A (en) 2022-06-17
SG10201703965SA (en) 2017-06-29
US9416172B2 (en) 2016-08-16
MX355107B (es) 2018-04-04
AU2015271749A1 (en) 2016-12-01
EP3154584B1 (en) 2021-08-04
US20220251175A1 (en) 2022-08-11
US11773157B2 (en) 2023-10-03
MX2016015812A (es) 2017-04-25
CA2950840C (en) 2023-09-26
CN108404128A (zh) 2018-08-17
US10214581B2 (en) 2019-02-26
CN106456763A (zh) 2017-02-22
KR20210047355A (ko) 2021-04-29
AU2015271749B2 (en) 2018-03-01
CN106456763B (zh) 2018-03-13
EP3970747A2 (en) 2022-03-23
KR101753553B1 (ko) 2017-07-03
US20190127449A1 (en) 2019-05-02
KR20190100471A (ko) 2019-08-28
JP6672221B2 (ja) 2020-03-25
ES2894867T3 (es) 2022-02-16
IL248959B (en) 2022-01-01
JP2020073548A (ja) 2020-05-14
KR20170007825A (ko) 2017-01-20
US20170015734A1 (en) 2017-01-19
US20200131252A1 (en) 2020-04-30
WO2015187779A1 (en) 2015-12-10

Similar Documents

Publication Publication Date Title
BR112016028043A2 (pt) composições farmacêuticas, e transportador farmaceuticamente aceitável e anticorpo monoclonal para igg3 humana ou humanizada
CY1122245T1 (el) Pd-1 αντισωμα, θραυσμα δεσμευσης αντιγονου αυτου, και ιατρικη εφαρμογη αυτου
BR112018067522A2 (pt) anticorpos específicos para receptor de poliovírus humano (pvr)
BR112018009064A2 (pt) anticorpo de pd-l1, fragmento de ligação ao antígeno do mesmo e aplicação médica do mesmo
EA201792221A1 (ru) Антитела против сортилина и способы их применения
BR112016027912A2 (pt) molécula de ligação triespecífica capaz de se ligar de maneira imunoespecífica a três epítopos diferentes, composição farmacêutica, método de tratamento de câncer, método de tratamento de uma doença associada à presença de um patógeno, anticorpo anti-ror1, ou fragmento de ligação a ror1, fragmento de anticorpo biespecífico, bite ou anticorpo de cadeia simples, e método de tratamento de câncer
MA55868A (fr) Anticorps monoclonal anti-ctla4 ou son fragment se liant à l'antigène, composition pharmaceutique et son utilisation
BR112018070919A2 (pt) anticorpos anti-tim-3 e composições
CU20170169A7 (es) Anticuerpos de factor xi
BR112017025080A2 (pt) composto conjugado de fármaco com anticorpo anti-cd123, composição conjugada de fármaco com anticorpo, método de tratamento de um paciente que tem um câncer que expressa cd123, composição farmacêutica, e, anticorpo intacto ou fragmento de ligação de antígeno
BR112016022841A8 (pt) Anticorpo igm, iga, igg / igm ou igg / iga, ou um fragmento de ligação ao antígeno do mesmo, composição que o compreende e uso do mesmo
BR112017003194B8 (pt) Anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga especificamente a lag3 humano, composição, e, uso do anticorpo ou de um fragmento de ligação ao antígeno do mesmo e da composição
PE20190737A1 (es) Anticuerpos anti-cd27
PE20200486A1 (es) Anticuerpos anti-cd33 y metodos para utilizarlos
BR112019010595A2 (pt) anticorpo ou fragmento de ligação ao antígeno do mesmo, combinação de moléculas de ácido nucleico isoladas, composição farmacêutica, kit, e, método para selecionar um composto.
BR112016026811A2 (pt) formulação de anticorpo
EA202091130A1 (ru) Лиофилизованный препарат моноклонального антитела к транстиретину
TW201613575A (en) Treatment of polybacterial infections
BR112019007147A2 (pt) anticorpos anti-o1 e usos dos mesmos
BR112016014163A2 (pt) anticorpos direcionados contra a toxina lukgh (lukab) de staphylococcus aureus e as sequências de anticorpos, seu uso no tratamento ou no diagnóstico de infecção por s. aureus, as preparações farmacêuticas e para diagnóstico, os ácidos nucleicos que codificam os anticorpos, o paratopo isolado dos anticorpos e o epítopo conformacional isolado
BR112020015498A8 (pt) Anticorpos anti-pd-1
BR112017021779A2 (pt) ?uma preparação combinada de anticorpos anti-staphylococcus aureus?
MX2021004173A (es) Combinaciones de anticuerpos dirigidos contra staphylococcus aureus.
WO2017075188A3 (en) Methods of using anti-alpha toxin antibody
BR112017007877A2 (pt) anticorpo ou fragmento do mesmo, epítopo em ccr6 humana solúvel, ácido nucleico isolado, célula hospedeira, método para produzir um anticorpo ou fragmento do mesmo, composição e imunoconjugado

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25D Requested change of name of applicant approved

Owner name: XBIOTECH INC. (CA)

B25K Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: republication

Owner name: XBIOTECH INC. (CA)

Free format text: RETIFICACAO DO DESPACHO (25.4) ? ALTERACAO DE NOME PUBLICADO NA RPI NO 2652, DE 03/11/2021, QUANTO A PETICAO NO PARECER.ONDE SE LE: 870210069076 DE 29/07/2021 DE 02/08/2021.LEIA-SE: 870210069073 DE 29/07/2021.

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/06/2015, OBSERVADAS AS CONDICOES LEGAIS